Navigation Links
Signalife Announces AFL Joins NIH Education Program
Date:6/17/2008

LOS ANGELES, June 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) and Athletes for Life Foundation announced that the Athletes for Life Foundation will conduct heart monitoring and screening at the Pontotoc Technology Center in Ada, Oklahoma. Willie Gault, Olympic gold medalist, Super Bowl champion, and a founder of the Athletes for Life Foundation, will be present on June 24-25th to participate in a children's health education program sponsored by the National Library of Medicine (NLM), a division of the National Institute of Health's (NIH).

The Athletes for Life Foundation has selected Signalife's award winning technology to perform heart monitoring and screening as part of the program's activities. The Signalife monitor is a 12 lead ambulatory ECG device capable of detecting subtle ECG changes that may be significant for early diagnosis of potential heart problems.

The Athletes for Life Foundation's co-founder, Willie Gault, commented: "I cannot begin to put into words how grateful I am to the NIH for inviting me to join their efforts in educating children. The foundation is bringing Signalife's heart monitoring and screening to the public, for free, as part of its continued effort to shift the healthcare balance from costly reactive heart disease treatments to early heart disease detection. A number of high profile sports and media personalities have recently passed away from heart disease. Perhaps use of this technology would have allowed life saving intervention. The foundation believes that providing annual heart screening for all people, before symptoms are apparent, can have an enormous impact in our efforts to save lives and lower the cost of healthcare throughout the world. We are thankful to all those who have supported our efforts to 'save lives, one heart at a time'."

About Athletes for Life Foundation

The Athletes for Life Foundation, http://www.athletesforlife.com, is a non-profit foundation whose membership includes a multitude of famous role models and athletes who have witnessed friends and colleagues die suddenly from cardiac disease. The Athletes for Life Foundation is committed to promoting early diagnosis and treatment of cardiac disease in order to save lives. The Athletes for Life Foundation is committed to bringing -- and does bring -- new technologies to healthcare. The Athletes for Life Foundation brings heart monitoring to communities, so that health care comes to the masses and not vice versa, in its mission to "save lives, one heart at a time."

Contact:

Athletes for Life Foundation:

Donations or event info:

Steve Cantrell

(562) 858-6717

AthletesforLife.com

About Signalife

Signalife, Inc., http://www.signalife.com, is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to develop medical devices that provide clear trusted data acquisition to enable accurate timely diagnosis of heart disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.signalife.com.

Contact:

Signalife, Inc.:

Investor relations

Michael Phillips

970-393-3996

info@signalife.com

Caution Regarding Forward-Looking Statement

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
2. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
3. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
4. Signalife Announces Webcast
5. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
6. Signalife Sees Accretive Purchase and Financial Commitments
7. Signalife Wins Second Frost & Sullivan Technology Award
8. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
9. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
10. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
11. U.S. Patent 7,299,083 Awarded to Signalife
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/5/2016)... FRANCISCO , February 5, 2016 ... a biotechnology company focused on developing products for ... has requested Rare Pediatric Disease Designation (RPDD) from the ... pigmentosa (RP) with MANF. MANF was previously granted orphan ... 2014. --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
Breaking Biology Technology:
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... Jan. 25, 2016  Glencoe Software, the world-leading supplier ... publication industries, will provide the data management solution OMERO ... Photo ... Phenotypic analysis measures the characteristics ... allowing comparisons between states such as health and disease, ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
Breaking Biology News(10 mins):